Results 131 to 140 of about 3,357,233 (168)

349 (PB337): IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets solid tumors with replication stress and DNA repair vulnerabilities

European Journal of Cancer
D.M. Munoz, M. Conway, V. Nagarajan, P. X. Lim, A.A. Rao, I. Shabalin, K. Trego, J. Ryan, R. Choy, M.J. Appel, P. Teriete, R. Zang, C. Frey, P. Barsanti, C. Neilan, M.A. White, R. Maskey   +16 more
semanticscholar   +1 more source

Pharmacological characterisation of novel, cell active, inhibitors of Poly(ADP-ribose glycohydrolase (PARG)

2014
Poly(ADP-ribose) glycohydrolase (PARG) is the only enzyme known to catalyse hydrolysis of the O-glycosidic linkages of ADP-ribose polymers, thereby reversing the effects of poly(ADP-ribose) polymerases. Total PARG deficiency leads to cell death whilst PARG depletion, using RNAi, leads to pleiotropic effects such as PAR chain persistence, progression of
Waddell, Ian, James, Dominic, Jordan, Allan, Hamilton, Nicola, McGonagle, Alison, Smith, Kate, Stowell, Alexandra, Waszkowycz, Bohdan, Ogilvie, Donald   +8 more
openaire   +1 more source

355 (PB343): Preclinical Candidate SYN608 - a Novel PARG Inhibitor with Excellent Anti-tumor Activity

European Journal of Cancer
S. Shi, X. Tang, H. He, C. Ge, Y. Cui, Y. Xie, C. Kan, S. Liu   +7 more
semanticscholar   +1 more source

Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors

Progress in Biophysics and Molecular Biology, 2021
Chris Brosey, Andrew Arvai, Panagiotis Katsonis   +2 more
exaly  

Abstract 5515:In vivoefficacy of the PARG inhibitor Gallotannin against triple negative breast cancer.

, 2013
T. Zhao, Qiang Sun, Amanda Lovato, S. D. Rincón, M. Witcher   +4 more
semanticscholar   +1 more source

Inhibition of PARG sensitizes ovarian cancer cells to PARP inhibitors and DNA damaging agents

Gynecologic Oncology, 2020
E. Matanes, L. Kogan, V. López-Ozuna, C. Mitric, O. Raban, N. Eisenberg, T. Baloch, S. Salvador, S. Lau, W.H. Gotlieb, A. Yasmeen   +10 more
openaire   +1 more source

340 (PB328): Discovery of NODX-010, a novel, potent PARG inhibitor demonstrating robust in vivo efficacy and the potential for new clinical settings that benefit patients with tumours resistant to PARP inhibitors

European Journal of Cancer
D. James, M. Debunne, J. Engel, A. Unger, C. Degenhart, P. Habenberger, A. Choidas, F. Ballaschk, U. Koch, J. Eickhoff, K. Dinkel, I. Waddell   +11 more
semanticscholar   +1 more source

Relationship of PARG with PARP, VEGF and b-FGF in colorectal carcinoma

Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2009
Ya-Lan Wang
exaly  

PIPERAZINE SUBSTITUTED INDAZOLE COMPOUNDS AS INHIBITORS OF PARG

2023
BARSANTI PAUL A, DILLON MICHAEL PATRICK, JAIPURI FIROZ ALI, XU YING-ZI, LINGHU XIN, ABED MONAH   +5 more
openaire   +2 more sources

PARG activity mediates intestinal injury induced by splanchnic artery occlusion and reperfusion

FASEB Journal, 2005
Salvatore Cuzzocrea, Rosanna Di Paola, Tiziana Genovese   +2 more
exaly